NAR Breakthrough Article

Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse

Frederic F. Depreux¹,†, Lingyan Wang²,†, Han Jiang²,†, Francine M. Jodelka¹, Robert F. Rosencrans³, Frank Rigo⁴,†, Jennifer J. Lentz³,⁵,†, John V. Brigande²,*,‡, and Michelle L. Hastings¹,*,‡

¹Department of Cell Biology and Anatomy, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA, ²Department of Otolaryngology, Oregon Hearing Research Center, Oregon Health & Science University, Portland, OR 97239, USA, ³Neuroscience Center of Excellence, LSU Health Sciences Center, New Orleans, LA 70112, USA, ⁴Ionis Pharmaceuticals, Carlsbad, CA 92010, USA and ⁵Department of Otorhinolaryngology, LSU Health Sciences Center, New Orleans, LA 70112, USA

Received April 27, 2016; Revised September 19, 2016; Accepted September 20, 2016

ABSTRACT

Congenital diseases account for a large portion of pediatric illness. Prenatal screening and diagnosis permit early detection of many genetic diseases. Fetal therapeutic strategies to manage disease processes in utero represent a powerful new approach for clinical care. A safe and effective fetal pharmacotherapy designed to modulate gene expression ideally would avoid direct mechanical engagement of the fetus and present an external reservoir of drug. The amniotic cavity surrounding the fetus could serve as an ideal drug reservoir. Antisense oligonucleotides (ASOs) are an established tool for the therapeutic modulation of gene expression. We hypothesize that ASOs administered to the amniotic cavity will gain entry to the fetus and modulate gene expression. Here, we show that an ASO targeting MALAT1 RNA, delivered by transuterine microinjection into the mouse amniotic cavity at embryonic day 13-13.5, reduces target RNA expression for up to 4 weeks after birth. A similarly delivered ASO targeting a causal splice site mutation for Usher syndrome corrects gene expression in the inner ear, a therapeutically relevant target tissue. We conclude that intra-amniotic delivery of ASOs is well tolerated and produces a sustained effect on postnatal gene expression. Transuterine delivery of ASOs is an innovative platform for developing fetal therapeutics to efficaciously treat congenital disease.

INTRODUCTION

Congenital disease and anomalies are estimated to cause 276,000 deaths worldwide within the first month of life (http://www.who.int/mediacentre/factsheets/fs370/en/). In 2015 alone, 5-20% of the 2.6 million global stillbirths can be attributed to genetic disease (1). Prenatal diagnosis early in gestation is becoming more feasible with the advent of increasingly non-invasive methods for obtaining fetal DNA samples (2). Given this ability to detect disease early in development, there is a growing interest in developing therapeutic strategies that can be applied in utero. Although there are some fetal interventions available for congenital structural defects using surgical interventions (3), there are few options for genetic disorders, which may have pathology beginning in utero. One limitation in the progress of in utero therapies is the challenge of managing risk to the fetus and pregnant female. Thus, model systems that can define safe and effective therapeutic strategies are needed. In utero stem-cell or gene therapies are currently being explored for the treatment of a limited number of diseases (4–
However, testing of pharmacologic agents in utero has been largely unexplored.

Antisense oligonucleotides (ASOs) are emerging as promising therapeutic molecules that meet many of the requirements of an ideal drug candidate including high specificity and stability, relatively low toxicity and ease of delivery to many tissues (7,8). ASOs are short, modified nucleic acids that are designed to target and bind to a specific RNA sequence via complementary base-pairing. Base-pairing to a target RNA can have a number of consequences depending on the binding location and the backbone chemistry of the ASO. For example, ASOs with DNA nucleotides can target an mRNA for degradation by RNase H, while ASOs with modified RNA bases can affect RNA splicing or translation by creating steric blocks to RNA binding proteins (9).

ASO technology has been used in mammalian cells to alter gene expression for therapeutic benefit (10). Some antisense drugs are in clinical use and many more are in development at various stages of clinical trials (8,11–14). Major advances in ASO chemistry have improved specificity, potency, stability, delivery and biodistribution, and toxic effects have been minimized (14,15). The favorable pharmacologic, pharmacokinetic and toxicological properties of ASOs make them a promising drug platform for disease therapeutics though their safety and efficacy in utero is not known.

ASOs are a particularly attractive drug option for diseases with known genetic components. The ASO mechanism of action is based on specific base-pairing to a gene sequence, and thus can be engineered to target and improve defective gene expression caused by mutations (7,10,11). In many cases, genetic diseases affect developmental processes or are associated with prenatal organ damage, as exemplified by many pediatric neurodegenerative and neurosensory disorders (16–20). Thus, there is a need for administration of therapeutics early in human development at either the embryonic or fetal stages. Such delivery modalities would ideally not engage the embryo or fetus directly and thus carry low risk of adverse events.

The exact mechanism by which ASOs enter cells is not entirely clear, thus it is difficult to predict the transuterine microinjection delivery modality that would be most effective. Previous studies have reported successful injections of ASO directly into mouse embryos (21), and ASOs are known to have widespread distribution in the body via this delivery method. Ideally, however, direct injection into an embryo or fetus would be avoided to minimize any potential risk of adverse outcomes. Studies have also suggested that ASO delivery to a pregnant mouse can result in very low but detectable amount of ASO in fetal liver only (22) and can affect gene expression in the developing embryo (23). However, the effect on postnatal expression was not evaluated. One drawback to prenatal maternal drug administration is that the exposure could lead to drug toxicity. One alternative approach for fetal drug administration that overcomes some of the disadvantages of other approaches is the delivery of ASO into the amniotic fluid contained within the amniotic cavity, which immediately surrounds the embryo. The biodistribution and bioactivity of ASOs delivered to the amniotic fluid has not been evaluated. This work seeks to understand the feasibility of using ASOs to treat pathologic conditions early in development in a manner that avoids potential complications associated with intra-embryonic injection.

In this study, we use a well-characterized ASO that targets a non-coding RNA, metastasis associated lung adenocarcinoma transcript 1 (MALAT1), to determine whether delivery of ASOs to the amniotic cavity can efficiently target gene expression. ASO-MALAT1 was selected because MALAT1 is highly expressed in many tissues but is dispensable in mice and the ASO has been shown to effectively lower MALAT1 RNA levels when delivered systemically (24,25). These features make ASO-MALAT1 an ideal tool to test the efficacy of ASO delivery to the amniotic cavity.

The MALAT1-targeted ASO (ASO-MALAT1) is a ‘gapmer’ oligonucleotide, comprised of a central block of 2′-deoxyribonucleotides that are flanked by 2′-O-methoxymethyl (2′-MOE) modified nucleotides. Upon base-pairing, the 2′-deoxy bases of the ASO render the target mRNA susceptible to cleavage by the ubiquitous cellular enzyme, RNase H, thereby reducing mRNA abundance. Intrapерitoneal injection of ASO-MALAT1 in mice and monkeys causes a reduction in target RNA levels in most tissues and cell types examined (25–27). In order to determine whether this highly active ASO can also downregulate MALAT1 when delivered in utero, we injected the ASO into the amniotic cavity at embryonic day 13-13.5 (E13-13.5) and assessed ASO distribution and MALAT1 RNA expression after birth. Transuterine microinjection of ASOs resulted in a significant reduction in MALAT1 RNA in neonatal mouse kidney, liver, and inner ear, and the effect persisted in the liver for at least 30 days after birth.

We further demonstrate the general ability of ASOs to target gene expression following injection into the amniotic cavity using another well-characterized ASO, ASO-Ush (previously ASO-29), which targets pre-mRNA generated from a mutated form of the Ushl c gene, Ushl c.216G>A (28). This mutation creates a de novo splice site that is used preferentially over the authentic splice site, which results in aberrant splicing and Usher syndrome in humans and mice. All of the ASO-Ush bases are 2′-MOE modified, and thus do not induce RNase H activity upon binding to target RNA, but rather create a steric block to splicing at the targeted position. ASO-Ush has been shown to block recognition of the de novo, aberrant splice site and thereby induce correct splicing of Ushl c.216A pre-mRNA in the inner ear and rescue hearing and balance abnormalities in mice following an intraperitoneal injection shortly after birth (28). Here, we show that injection of ASO-Ush to the amniotic cavity corrects Ushl c.216A pre-mRNA splicing in the inner ear of postnatal mice. Taken together, the ASO-MALAT1 and ASO-Ush data demonstrate the general ability of ASOs to access embryonic tissue and modulate gene expression after birth. Our results suggest that ASOs may have potential as fetal pharmacotherapeutics to effectively modulate postnatal RNA metabolism.

MATERIALS AND METHODS

Oligonucleotides

A chimeric (gapmer) oligonucleotide (5′-CGGTGCAAGG CTTAGGAATT-3′) targeted to murine MALAT1 RNA
(ASO-MALAT1) with a fully-modified phosphorothioate backbone with 2'-MOE substituted nucleotides at positions 1–5 and 16–20, and 2'-deoxynucleotides at positions 6–15, were synthesized as previously described (25). ASO-C (5’-TTAGTTAATCAGCCTG-3’) and ASO-Ush (ASO-29) (5’-AGCTGATCATATCTACC-3’) have a fully-modified phosphorothioate backbone with 2'-MOE modifications at all positions as previously described (28,29).

Animals

All procedures on mice were conducted to minimize pain and discomfort by the use of anesthesia and prophylactic analgesia in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal care protocols governing this study were approved by the Oregon Health & Science University and Rosalind Franklin University Institutional Animal Care and Use Committees.

For experiments with MALAT1-ASO, CD-1 (ICR) female mice were crossed with male C57BL/6J mice and for ASO-Ush experiments, heterozygous Ush1c<sup>c16A</sup> females were crossed with homozygous Ush1c<sup>c16AA</sup> males (28).

Intra-amniotic cavity injections

ASO-MALAT1, ASO-C or ASO-Ush were microinjected into the amniotic cavity of E13.15 conceptuses generated by time-dependent crosses (E0.5 was considered noontime on the day a vaginal plug was detected).

Dams were subjected to transuterine microinjection in the context of mouse survival surgery as described previously (30,31). Aqueous ASOs were mixed with crystalline fast green tracer dye that dissolved fully in solution without appreciably diluting ASO concentration. The ASO-fast green solution was microinjected with a Picospritzer bevel (32–34). Each pipette was independently calibrated before use so that a known volume and thus a known dose of ASO was delivered per amniotic cavity (34,35). Supplementary Movie S1 and Figure 1 demonstrate the injection paradigm used to deliver ASOs to the amniotic cavity and the embryo line art therein is after Kaufman (36) (Supplementary Movie S1, Figure 1A).

Intraperitoneal injections

Mice were genotyped using ear punch tissue and polymerase chain reaction (PCR) as described previously (28). Mouse pups were injected with 300 mg kg<sup>−1</sup> of ASO-Ush at postnatal day 5 (P5) by intraperitoneal injection as previously described (28).

Tissue harvest and handling

Tissue for ASO quantification and RNA isolation was rapidly dissected following euthanasia, distributed to 2.0 ml cryogenic vials, and snap frozen on liquid nitrogen. Tissue was stored at −80°C until shipment on dry ice from Oregon to collaborators in either Illinois or California. Tissue for immunofluorescence was rinsed in phosphate buffered saline (PBS) (pH 7.2–7.4, calcium and magnesium free), fixed overnight in 4% paraformaldehyde in PBS with gentle rotation and rinsed three times in PBS. Tissue was stored at 4°C until shipment in PBS at 4°C to Louisiana.

Quantification of ASO tissue concentration

ASO concentration was determined by HPLC with mass spectrometry detection as previously described (25).

RNA analysis

Frozen tissues were homogenized in TRIZOL solution (ThermoFisher Scientific) using a PowerGen 1000 Homogenizer (ThermoFisher Scientific). Total RNA was purified from TRIZOL reagent following manufacturer’s recommendations. RNA was quantitated and purity assessed (A260/A280) using a Biophotometer (Eppendorf). The RNA (1 μg) was reverse transcribed using oligo-dt primer and GoScript reverse transcriptase (Promega) following manufacturer’s recommendations.

Real time PCR. RNA was quantitated and analyzed by real-time quantitative PCR using TaqMan Gene Expression Master Mix and Primer/Probe set for mouse MALAT1 (Mm01279712_s1) or β-actin (ACTB, Applied Biosystem). Amplification was performed in 96-well plates using the standard condition (50°C for 2 min, and then two steps over 40 cycles at 95°C for 15 s and 60°C for 1 min) for the V1A7 AB Thermocycler (Applied Biosystem). Each sample was analyzed in duplicate or triplicate. Comparative Ct analysis (ΔΔCt) using ACTB as a normalizer transcript was applied to calculate the relative amount (RQ) of MALAT1 mRNA in samples from mice treated with ASO-MALAT1 compared to mice treated with ASO-C. Values that were more than two standard deviations from the mean were not considered, which applied to one sample from the ear at 80 μg and one sample from the spinal cord at 80 μg.

Semiquantitative PCR. One microliter of cDNA was used in PCR reactions with GoTaq Green (Promega) supplemented with primers and α<sup>32</sup>P-dCTP. Primers specific for human Ush1c exon 3 (5’-GAATATGATCGCTGCCGAC-3’) and mouse exon 5 (5’-GCATGATGATGATTCTCTTC-3’) were used to specifically amplify only mRNA generated from the knocked-in allele of the human Ush1c<sup>216A</sup> gene, which is only present in correctly spliced mRNA (28). Mouse Gapdh primers (5’-GGATGCGCCGTGCTGATG-3’) and (5’-GCCTAAAATTGTCATGCTGAC-3’) were used to detect and measure endogenous murine Gapdh mRNA. Products were separated on a 6% non-denaturing polyacrylamide gel and quantitated using a Typhoon 9400 phosphorimager (GE Healthcare). Ush1c values were divided by Gapdh values and represented graphically following normalization to the Ush1c/Gapdh ratio of one intraperitoneal sample.

Immunohistochemistry

Tissues were harvested from P7 pups and fixed in 4% paraformaldehyde in PBS, cryoprotected in an ascending
RESULTS

Transuterine microinjection of ASO-MALAT1 into the amniotic cavity of mouse embryos

We previously showed effective gene transfer to the developing mouse inner ear by electroporation- or virus-mediated approaches (30,32). We adapted our gene transfer approach to test a fetal pharmacotherapy paradigm in which an ASO targeting MALAT1 (ASO-MALAT1), or a control ASO (ASO-C) lacking cellular targets, was delivered by transuterine microinjection into the amniotic cavity surrounding the E13-13.5 mouse embryo. We hypothesized that the amniotic cavity would serve as a biological reservoir for sustained ASO delivery to the developing fetus from the organogenesis stage until birth. ASO-MALAT1 was selected as a test ASO because it has been well-characterized in vivo following systemic delivery to adult mice (25).

A micropipette containing aqueous ASO tinted with fast green tracking dye was advanced through the uterus, visceral yolk sac and amnion where it drapes over the forebrain and left forelimb (Figure 1A, B and Supplementary Movie S1). In a representative embryo dissected free of the uterus immediately after microinjection of ASO into the amniotic cavity, tracking dye obscured facial features and collected around the pinna or auricle of the external ear (Figure 1C). Dissection of the visceral yolk sac did not alter dye localization (Figure 1D), indicating that the exocoelomic cavity, tracking dye obscured facial features and collected around the pinna or auricle of the external ear (Figure 1C).

Statistical analyses

Statistical analyses were performed as described in the text and figure legends using GraphPad Prism 6 v6.0h. One sample or two sample $t$-tests were used to determine significant differences between the test and control data sets, as indicated in figure legends. One-way analysis of variance (parametric) or Kruskal–Wallis tests (non-parametric) were used to compare three or more groups after data sets were checked for normality with the Kolmogorov–Smirnov test to determine whether parametric tests or non-parametric tests should be used. Correction for multiple comparisons was used (Bonferroni’s for parametric; Dunn’s for non-parametric) as indicated in the text. Significance is reported with an $\alpha$-level of 0.05.
ASO-MALAT1 is detected in postnatal tissue following ASO microinjection into the amniotic cavity

We next assessed whether ASOs that are injected into the amniotic cavity at E13-13.5 gain access to the embryo and are subsequently detectable in neonatal tissue after birth. We measured the ASO concentration in nine different tissues from P7 mice following exposure to 80 μg of ASO via amniotic cavity microinjection at E13-13.5. ASO-MALAT1 was most abundant in the liver tissue (56 ± 0.5125) and kidney (6.35 ± 0.136) tissues from P7 mice following exposure to 80 μg of ASO-MALAT1 or ASO-C was injected into the amniotic cavity at E13-13.5 and liver, kidney, inner ear and brain were collected at P1, P7, P15 and P30 for MALAT1 RNA quantitation. MALAT1 RNA was significantly reduced at all four time points in the liver; at P1 and P7 in kidney tissue; and at P7 and P15 in the inner ear (Figure 4A). There was not a significant difference among the P1, P7 and P15 time points in liver, but there was a significant difference in MALAT1 RNA abundance in P1, P7 and P15 compared to P30 tissue, indicating that the reduction in MALAT1 RNA in the liver diminished over time (Figure 4B).

The effect of ASO-MALAT1 on MALAT1 RNA abundance in the kidney was less stable, with MALAT1 RNA nearing control levels by P15 (Figure 4A). A comparison between the time-points in kidney tissue revealed a significant decrease in MALAT1 RNA abundance in P1 and P7 tissue compared to P30 tissue (Figure 4B). In the inner ear, there was a trend towards an increase in MALAT1 RNA between P15 and P30, suggesting a decline in ASO targeting during this timeframe (Figure 4B). MALAT1 RNA was not significantly reduced in the brain at any of the time-points evaluated (Figure 4A, B).

ASO-MALAT1 distribution in liver, kidney and brain after delivery to the amniotic cavity at E13-13.5

To assess the presence and distribution of ASO in the tissues of postnatal mice that received ASO in the amniotic cavity, immunofluorescence labeling of ASO-MALAT1 was performed using an antibody that specifically recognizes the ASO phosphorothioate backbone (25). We assessed ASO localization in the tissues of P7 mice following an E13-13.5 intra-amniotic cavity injection of 80 μg of ASO (Figure 5 and Table 2). In the liver, ASO was broadly distributed throughout the tissue in both non-parenchymal cells and some hepatocytes. In the kidney, ASO was detected in proximal epithelial cells in some tubules. In the brain, ASO was localized to ventricular ependymal cells. These results show that ASO delivered to the amniotic cavity localizes to the P7 liver, kidney and the brain ventricle.

Correction of Ush1c.216A mRNA splicing following injection of ASO-Ush into the amniotic cavity

We have shown previously that treatment of neonatal mice by intraperitoneal injection of a single dose of an ASO targeting an aberrant splice site created by the mutation Ush1c.c.216G>A redirects splicing to the authentic splice site and partially corrects Ush1c.c.216A splicing in a therapeutically relevant target tissue, the inner ear (28). Because delivery of MALAT1-ASO into the amniotic cavity resulted in a significant downregulation of MALAT1 RNA in the inner ear, we

Table 1. ASO-MALAT1 tissue concentration

| Organ           | Concentration (μg/g; mean ± s.e.m.) | Ratio to liver | Tissue total (μg; mean ± s.e.m.) |
|-----------------|------------------------------------|---------------|---------------------------------|
| Liver           | 56.1 ± 22.2                        | 1             | 6.821 ± 0.5125                  |
| Kidney          | 6.35 ± 1.44                        | 0.136         | 0.1345 ± 0.0074                 |
| Lung            | 4.04 ± 0.69                        | 0.105         | 0.3100 ± 0.0170                 |
| Eye             | 1.64 ± 0.59                        | 0.036         | 0.0009 ± 0.0005                 |
| Heart           | 1.46 ± 0.39                        | 0.031         | 0.0354 ± 0.0019                 |
| Spinal cord     | 1.21 ± 0.54                        | 0.027         | 0.0323 ± 0.0020                 |
| Inner ear       | 1.01 ± 0.35                        | 0.023         | 0.0010 ± 0.0009                 |
| Skeletal muscle | 0.74 ± 0.44                        | 0.010         | 0.0014 ± 0.0008                 |
| Brain           | 0.13 ± 0.03                        | 0.003         | 0.0032 ± 0.0025                 |

n = 5, except ear and spinal cord where n = 4.
tested whether the ASO targeting Ush1c c.216A (ASO-Ush) could correct splicing of the RNA transcript in the inner ear when delivered by transuterine microinjection into the amniotic cavity.

E13-13.5 embryos from a heterozygous Ush1c216GA female crossed with a homozygous Ush1c216AA male were injected with 100 µg of ASO-Ush and inner ear tissue was collected and analyzed at P22. For comparison, neonatal Ush1c216AA mice were treated by intraperitoneal injection of 300 mg/kg (~600 µg) of ASO-Ush at P5 and tissues were collected at P22. Correct Ush1c splicing was detected in all of the samples from mice injected with ASO-Ush at E13-13.5 indicating successful delivery of the ASO to the inner ear by delivery to the amniotic cavity (Figure 6). The amount of correctly spliced Ush1c216A mRNA that was detected in the inner ear of mice treated by delivery to the am-
**DISCUSSION**

Our results demonstrate that ASOs injected into the amniotic cavity at E13-13.5 can alter expression of a targeted RNA transcript in the liver, kidney, and inner ear of postnatal mice. We find that an ASO delivered in this manner to mouse embryos can effectively target RNA for 1 (kidney), 2 to 3 (inner ear) or 4 weeks (liver) after birth. We have demonstrated the efficacy of ASO delivery to the amniotic cavity using an ASO that targets the long non-coding RNA, MALAT1, for RNase H-mediated degradation and an ASO that binds its target RNA creating a steric block of cryptic splicing of pre-mRNA from the Ush1c.216A gene. We propose that this approach can be applied to the use of ASOs, in general, for modulation of any gene target. Our data suggest that intra-amniotic cavity injection of ASOs represents a relatively non-invasive modality for the treatment of congenital disease or other conditions that adversely affect fetal growth and development.

Fetal approaches for treating genetic disease are desirable for the prevention of antenatal pathology that can cause irreversible damage in utero. In addition, prenatal treatment would be expected to target a rapidly dividing population of stem or progenitor cells that may be more easily accessed by ASOs than post-mitotic differentiated cell types. Injection into the amniotic cavity is likely to have as favorable a benefit/risk balance as amniocentesis, a diagnostic test involving removal of amniotic fluid, which carries a low miscarriage rate of ~1 in 1000 (0.11%) (40). In utero therapies involving delivery of reagents to the amniotic cavity are not common but the approach is under increasing consideration as new promising therapeutic interventions become available for the treatment of disorders in early development (4,41–43).
Figures 5. Distribution of ASO in P7 liver, kidney and brain after microinjection of ASO-MALAT1 into the E13-13.5 amniotic cavity. Immunofluorescence detection of ASO-MALAT1 in (A) liver (B) kidney and (C) brain. Control panels represent tissues from age-matched uninjected mice. F-actin (red, phalloidin) was labeled in the kidney and liver and glial cells in the brain were immunolabeled with glial-fibrillary acidic protein (GFAP). Nuclei are counterstained with DAPI (blue). BB: brush border; BD: biliary duct; EC: ependymal cells; GM: glomerulus; H: hepatocyte; NP: non-parenchymal cell; PT: proximal tubule cells; PV: portal vein. Scale bars = 100 μm and apply to panels in each respective column.

Figure 6. Ush1c c.216A splicing in the inner ear of P22 mice dosed with ASO-Ush by amniotic cavity injection at E13-13.5. (A) Semi-quantitative radiolabeled RT-PCR analysis with primer sets specific for human USH1C (to specifically amplify only the knocked in human portion of the Ush1c<sup>c.216A</sup> allele (28)) and mouse Gapdh was performed on RNA isolated from the inner ear of P22 Ush1c<sup>c.216A</sup> or Ush1c<sup>c.216A</sup> mice treated with ASO-Ush at E13-13.5 by transuterine injection to the amniotic cavity (IA) (n = 3), or neonatal Ush1c<sup>c.216A</sup> mice treated at P5 with ASO-Ush by intraperitoneal (IP) injection (n = 3), or untreated P22 Ush1c<sup>c.216A</sup> (control) (n = 3) mice. (B) Quantification of correctly spliced mRNA from the Ush1c<sup>c.216A</sup> allele. Error bars represent s.e.m (n = 3). *P ≤ 0.05, one-tailed, two-sample t-test.

In the present study, 94% (89/95) of the ASO-MALAT1 or ASO-C injected embryos survived, all of which were indistinguishable from uninjected controls. These results demonstrate that transuterine microinjection of ASOs into the amniotic cavity is a feasible methodology for fetal drug delivery made possible by the specialized properties of the amnion, a membrane that encases the mammalian embryo. The mouse amnion is a clear, bilayered membrane that develops from the amniochorionic fold during gastrulation (44). The shear resistance and strength of the amnion results from the fusion of a layer of cuboidal ectoderm that faces the surface of the embryo and a layer of squamous mesoderm that faces the exocoelomic cavity (44). This structure is resistant to mechanical perturbation and self-seals after puncture with a 10–40 micron microinjection pipette by immediately clogging with cells present in the amniotic fluid. The amnion further defines a cavity surrounding the embryo that has a comparatively large volume of ∼ 85–95 microliters at E13-13.5 (ref. (45)), allowing sufficient space to load the cavity with a relevant quantity of bioactive ASO for
delivery to the embryo. Finally, the diverse solute concentration of the amniotic fluid, consisting of sodium, potassium, chloride, glucose, lactate, bicarbonate and calcium as well as nutrients and factors that promote fetal growth, produces an osmolality of 300–305 mOsm/kg from E13-17 (45) which is similar to the osmolality of mouse blood plasma at 327 mOsm/kg (46), thus ensuring a corollary pharmacokinetic environment for ASO mobilization that is well established from systemic ASO injection studies (47). Our work establishes that the amniotic cavity has the patency, volume and solute concentration to serve as an efficient biological reservoir for ASO delivery to the developing embryo.

The mechanism by which ASOs in the amniotic cavity gain access to the embryo is not clearly understood. ASOs with a phosphorothioate-modified backbone bind to plasma proteins after systemic delivery, which slows their renal clearance and permits broad distribution in tissues, with the highest accumulation seen in the liver and kidney following subcutaneous or intravenous injection (25,47,48). Our study demonstrates that intra-amniotic cavity injection of ASOs results in a similar liver and kidney enrichment. We hypothesize that the ASOs in the amniotic cavity gain entry into the circulatory system of the fetus and subsequently become enriched in hepatic and renal tissues. The ∼25 mOsm/kg differential between the osmolality of the amniotic cavity fluid and mouse blood plasma may establish an osmotic gradient that produces a strong hydrostatic force to efficiently drive water directly into blood vessels of the fetal skin, the umbilical cord and the embryonic component of the placenta (49,50). Remarkably, this so-called intramembranous transport pathway drives 400 ml of water into the sheep fetal circulation per day (30). In the E13-13.5 mouse fetus, the intramembranous transport pathway through the skin is restricted due to keratinization which occurs at approximately E12.5-14 in rodents (51). It is thus likely that the bulk of water transport in the E13-13.5 mouse embryo occurs through the fetal placenta or umbilicus. We predict that the strong hydrodynamic flow of water into the fetal circulation supports ASO translocation from the amniotic cavity to the fetal blood stream. A more complete understanding of fetal ASO transport may enable its modulation to enhance fetal uptake, broaden tissue distribution and heighten therapeutic impact.

ASO pharmacokinetics and pharmacodynamics in the pre-natal and neonatal mouse are complex and not fully understood, and thus the amount of ASO in any given tissue or organ and the extent of the anticipated ASO-mediated RNA modulation may not reliably predict phenotypic effects. For example, we have recently shown that only a very low level of ASO targeting was necessary to achieve a complete phenotypic rescue of vestibular dysfunction and partial rescue of hearing in a mouse model of Usher syndrome (28). Considering these previous results, it is particularly encouraging to find that the intra-amniotic cavity delivery of ASO results in a significant effect on the target RNA in the inner ear, which would be the target tissue to treat congenital forms of deafness such as that seen in human Usher syndrome. Indeed, effective ASO delivery via amniotic cavity injection was confirmed using an ASO targeting the aberrant splice site in Ush1c.c216A that is associated with Type 1C Usher syndrome. This ASO, which has been previously shown to correct splicing and rescue vestibular and hearing deficits in the mice when delivered by intraperitoneal injection shortly after birth, caused a greater correction of splicing when delivered by intra-amniotic cavity injection. We are currently refining fetal delivery of ASO-Ush to further enhance targeting of the Ush1c.c216A allele and to determine the impact on ameliorating the deleterious sensory phenotypes.

We conclude that ASO delivery to the intra-amniotic cavity modulates neonatal gene expression and may serve as a therapeutic intervention in itself or when paired with a suitable postnatal therapeutic strategy. Further optimization of the method will broaden the potential impact and applicability of this approach. We predict that fetal ASO pharmacotherapy has the potential to safely enable therapeutic strategies for the treatment of fetal and congenital genetic disease.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

We thank Steven Miller for assistance with data analysis and statistics, Viktoriya Georgieva and Anthony Hinrich for experimental assistance and consultation and Monica Oblinger for comments on the manuscript. M.L.H., J.V.B., F.R. and J.J.L. conceived and designed the experiments and analyzed the data. F.F.D., L.W., H.J., F.M.J. and R.F.R. performed the experiments and analyzed the data. F.F.D., M.L.H. and J.V.B. wrote the manuscript.

FUNDING

National Institutes of Health [R01-DC012596 to M.L.H., R21-DC012916 to J.V.B., R01-DC014160 to J.V.B., P30-DC005983 to J.V.B., 1 U54 GM104940 to J.J.L., P30-GM103340 to J.J.L.]; Foundation Fighting Blindness (to J.J.L., M.L.H.). Funding for open access charge: The open access publication charge for this paper has been waived by Oxford University Press—NAR Editorial Board members are entitled to one free paper per year in recognition of their work on behalf of the journal.

Conflict of interest statement. Frank Rigo is an employee of Ionis Pharmaceuticals. Michelle Hastings receives funding from Ionis Pharmaceuticals.

REFERENCES

1. Lawn,J.E., Blencowe,H., Waiswa,P., Amouzou,A., Mathers,C., Hogan,D., Flenady,V., Frenø,J.F., Qureshi,Z.U., Calderwood,C. et al. (2016) Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet, 387, 587–603.
2. Bianchi,D.W. (2012) From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat. Med., 18, 1041–1051.
3. Pearson,E.G. and Flake,A.W. (2013) Stem cell and genetic therapies for the fetus. Semin. Pediatr. Surg., 22, 56–61.
4. Ramachandran,D.L., Shaw,S.S., Shangaris,P., Loukogeorgakis,S., Guilhot,P.V., Coppi,P.D. and David,A.L. (2014) In utero therapy for congenital disorders using amniotic fluid stem cells. Front. Pharmacol., 5, 270–281.
27. Wheeler, T.R., Rahim, A.A., Buckley, S.M., Ward, N.J., Chan, J.K., Howe, S.J. and Waddington, S.N. (2011) Perinatal gene transfer to the liver. *Curr. Pharm. Des.*, 17, 2528–2541.

28. Pergament, E. (2014) The future of prenatal diagnosis and screening. *J. Clin. Med.*, 3, 1291–1301.

29. Rigo, F., Seth, P.P. and Bennett, C.F. (2014) Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. *Adv. Exp. Med. Biol.*, 825, 303–352.

30. Havens, M.A. and Hastings, M.L. (2016) Splice-switching antisense oligonucleotides as therapeutic drugs. *Nucleic Acids Res.*, 44, 6549–6560.

31. Beaudet, A.L. and Meng, L. (2015) Gene-targeting pharmaceuticals for single-gene disorders. *Hum. Mol. Genet.*, 25, R18–R26.

32. Havens, M.A., Duelli, D.M. and Hastings, M.L. (2013) Targeting RNA splicing for disease therapy. *Wiley Interdiscip. Rev. RNA*, 4, 247–266.

33. Lundin, K.E., Gissberg, O. and Smith, C.I. (2015) Oligonucleotide therapies: the past and the present. *Hum. Gene Ther.*, 26, 475–485.

34. Geary, R.S., Baker, B.F. and Crooke, S.T. (2015) Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(R)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. *Clin. Pharmacokinet.*, 54, 133–146.

35. Marafini, I., Di Fusco, D., Calabrese, E., Sedda, S., Pallone, F. and Monteleone, G. (2015) Antisense approach to inflammatory bowel disease: prospects and challenges. *Drugs*, 75, 723–730.

36. McCloud, G. and Wood, M.J. (2015) An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. *Curr. Opin. Pharmacol.*, 24, 52–58.

37. Juliano, R.L. (2016) The delivery of therapeutic oligonucleotides. *Nucleic Acids Res.*, 44, 6518–6548.

38. Poretti, A., Boltsmeiser, E. and Huismann, T.A. (2016) Pre- and postnatal neuroimaging of congenital cerebellar abnormalities. *Cerebellum*, 15, 5–9.

39. Utz, J.R., Crutchter, T., Schneider, J., Sorgen, P. and Whiteley, C.B. (2015) Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses. *Mol. Genet. Metab.*, 114, 274–280.

40. Braverman, N.E., Raymond, G.V., Rizzo, W.B., Moser, A.B., Wilkinson, M.E., Stone, E.M., Steinberg, S.J., Wangler, M.F., Rush, E.T., Hacia, J.G. et al. (2016) Peroxisome biogenesis disorders in the Zellweger spectrum: an overview of current diagnosis, clinical manifestations, and treatment guidelines. *Mol. Genet. Metab.*, 117, 313–321.

41. Poenaru, L., Castelnau, L., Dumez, Y. and Thepot, F. (1984) First-trimester prenatal diagnosis of mucolipidosis II (I-cell disease) by chorioryphic biopsy. *Am. J. Hum. Genet.*, 36, 1379–1385.

42. Hermes, K., Schneider, P., Krieg, P., Dang, A., Huttner, K. and Schneider, H. (2014) Prenatal therapy in developmental disorders: drug targeting via intra-amniotic injection to treat X-linked hypohidrotic ectodermal dysplasia. *J. Investig. Dermatol.*, 134, 2985–2987.

43. Ross, M.G., Brace, R.A. and National Institute of Child, H. and Development Workshop, P. (2001) National Institute of Child Health and Development Conference summary: amniotic fluid biology–basic and clinical aspects. *J. Matern. Fetal Med.*, 10, 48–55.

44. Beckvold, C.M., Robertson, K.L., Reinhard, M.K., Battles, A.H. and Rowland, N.E. (2013) Dehydration parameters and standards for laboratory mice. *J. Am. Assoc. Lab. Anim. Sci.*, 52, 233–239.

45. Geary, R.S. (2009) Antisense oligonucleotide pharmacokinetics and metabolism. *Expert Opin. Drug Metab. Toxicol.*, 5, 381–391.

46. Lentz, J.J., Jodelka, F.M., Hinrich, A.J., McCallfrey, K.E., Farriss, H.E., Spalitta, M.J., Bazan, N.G., Duelli, D.M., Rigo, F. and Hastings, M.L. (2013) Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness. *Nat. Med.*, 19, 345–350.

47. Hinrich, A.J., Jodelka, F.M., Chang, J.L., Brumman, D., Brumman, A.M., Briggs, C.A., James, B.D., Stutzmann, G.E., Bennett, D.A., Miller, S.A. et al. (2016) Therapeutic correction of ApoER2 splicing in Alzheimer’s disease mice using antisense oligonucleotides. *EMBO Mol. Med.*, 8, 328–345.

48. Jiang, H., Wang, L., Bove, K.T., Cepko, C.L., Fekete, D.M. and Brindge, J.V. (2013) Lineage analysis of the late otocyst stage mouse inner ear by transuterine microinjection of a retroviral vector encoding alkaline phosphatase and an oligonucleotide library. *PLoS One*, 8, e69314.
48. Geary, R.S., Norris, D., Yu, R. and Bennett, C.F. (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev., 87, 46–51.

49. Brace, R.A. (1995) Progress toward understanding the regulation of amniotic fluid volume: water and solute fluxes in and through the fetal membranes. Placenta, 16, 1–18.

50. Brace, R.A. (1997) Physiology of amniotic fluid volume regulation. Clin. Obstet. Gynecol., 40, 280–289.

51. Hayward, A.F. (1983) The permeability of the epithelium of the skin of fetal rats demonstrated with a lanthanum-containing solution. J. Anatomy, 136, 379–388.